Pulmonary and Systemic Immune Profiles Following Lung Volume Reduction Surgery and Allogeneic Mesenchymal Stromal Cell Treatment in Emphysema

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 19; p. 1636
• Main Authors: Jia, Li, Li, Na, van Unen, Vincent, Zwaginga, Jaap-Jan, Braun, Jerry, Hiemstra, Pieter S, Koning, Frits, Khedoe, P Padmini S J, Stolk, Jan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30-09-2024; MDPI
• Subjects: Aged; B cells; Bone marrow; bone marrow-derived mesenchymal stromal cells (BM-MSCs); Bone mass; Bone surgery; CD163 antigen; CD4 antigen; CD8 antigen; Cells; Chronic obstructive pulmonary disease; Data analysis; Effector cells; Emphysema; Emphysema, Pulmonary; Female; Health aspects; Humans; Immunological memory; Inflammation; Inflammatory diseases; Intravenous administration; Lung - immunology; Lung - pathology; Lung diseases; lung volume reduction surgery (LVRS); Lungs; Lymphocytes; Lymphocytes T; Macrophages; Male; mass cytometry by-time-of-flight (CyTOF); Memory cells; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - immunology; Middle Aged; Patients; Placebos; Pneumonectomy; Pulmonary Emphysema - immunology; Pulmonary Emphysema - surgery; Pulmonary Emphysema - therapy; pulmonary immune profile; Respiratory agents; Software; Stem cells; Surgery; systemic immune profile; Transplantation, Homologous; Netherlands; mass cytometry by-time-of-flight (CyTOF); bone marrow-derived mesenchymal stromal cells (BM-MSCs); lung volume reduction surgery (LVRS); systemic immune profile; pulmonary immune profile; emphysema
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells13191636

Emphysema in patients with chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation. Preclinical studies suggest that lung volume reduction surgery (LVRS) and mesenchymal stromal cell (MSC) treatment dampen inflammation. We investigated the effects of bone marrow-derived MSC (BM-MSC) and LVRS on circulating and pulmonary immune cell profiles in emphysema patients using mass cytometry. Blood and resected lung tissue were collected at the first LVRS (L1). Following 6-10 weeks of recovery, patients received a placebo or intravenous administration of 2 × 10
cells/kg bodyweight BM-MSC (n = 5 and n = 9, resp.) in week 3 and 4 before the second LVRS (L2), where blood and lung tissue were collected. Irrespective of BM-MSC or placebo treatment, proportions of circulating lymphocytes including central memory CD4 regulatory, effector memory CD8 and γδ T cells were higher, whereas myeloid cell percentages were lower in L2 compared to L1. In resected lung tissue, proportions of Treg (
= 0.0067) and anti-inflammatory CD163
macrophages (
= 0.0001) were increased in L2 compared to L1, while proportions of pro-inflammatory CD163
macrophages were decreased (
= 0.0004). There were no effects of BM-MSC treatment on immune profiles in emphysema patients. However, we observed alterations in the circulating and pulmonary immune cells upon LVRS, suggesting the induction of anti-inflammatory responses potentially needed for repair processes.